🇺🇸 FDA
Pipeline program

Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose

CTP-VLP-002

Phase 2 mab active

Quick answer

Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose for Poliomyelitis is a Phase 2 program (mab) at CanSino Biologics with 1 ClinicalTrials.gov record(s).

Program details

Company
CanSino Biologics
Indication
Poliomyelitis
Phase
Phase 2
Modality
mab
Status
active

Clinical trials